English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We present the results after surgery for gallbladder adenocarcinoma in our centre. The Total Risk Score (TRS) is a useful index to predict the amount of residual disease that is observed in reinterventions with curative intent that are carried out in these tumors. MATERIAL AND METHODS Retrospective study of cases and controls. Review of 2019 patients who underwent cholecystectomy from 2012 to 2019 in a Hepatobiliopancreatic Surgery Unit. Exposure of a total of 75 patients for the study (15 cases versus 60 controls, 1: 4 ratio). RESULTS 15 patients were diagnosed with gallbladder adenocarcinoma, 10 of which were incidental (66.7%). Oncological resection was R0 in 93.33% of the cases and R1 in the remaining 6.67%. TRS was low in 9% of cases, moderate in 45.45%, and high in another 45.45%. The rate of reoperation with oncological intention is 60% in our series (9 patients), and residual disease was observed in 4 of them (44.4%). In 3 of the patients, an exploratory laparotomy was performed without associated resection due to the extent of the disease (33.3%). The percentage of R0 after reoperation was 77.7%. The median survival after surgery is 38.67 months (95% confidence interval (29.73 - 67.34). CONCLUSIONS The study of the pathological tissue results for the performance of revision surgery could guide the oncological attitude in the future if its validity is confirmed with more multicentre studies.

GALLBLADDER ADENOCARCINOMA. CURRENT STATUS OF THE NEW FORECAST FACTORS AND THEIR IMPACT ON SURVIVAL. CASES AND CONTROLS STUDY